The trademark application LEBVAIYA was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on September 20, 2021, and it was registered by office on December 28, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders
Pharmaceutical preparations for the treatment, prevention and/or diagnosis of cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders
Pharmaceutical preparations for the treatment, prevention and/or diagnosis of fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders
Pharmaceutical preparations for the treatment, prevention and/or diagnosis of neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases
Diagnostic agents, preparations and substances for medical purposes
Diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use
Radiopharmaceutical diagnostic preparations for medical use
Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases